Atrial Fibrillation – Global Clinical Trials Review, H2, 2021
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
GlobalData’s clinical trial report provides an overview of the atrial fibrillation clinical trials scenario. This report provides top-line data relating to the clinical trials on atrial fibrillation. The report includes an overview of trial numbers and their average enrolment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status, and sponsor type. The report also provides prominent drugs for in-progress trials (based on the number of ongoing trials). The report enhances the decision-making capabilities and helps to create effective counterstrategies to gain a competitive advantage.
The Atrial Fibrillation clinical trial report consists of 1742 trials. Trials conducted by companies in Phase IV, Phase III, Phase II, Phase I, and Phase 0 stand at 233, 133, 167, 271, and 2 respectively. Similarly, the trials with different status compile of Completed – 1118, Ongoing – 302, Planned – 120, Suspended – 3, Terminated – 108, and withdrawn – 91. Out of 1118 completed trials 632 trials have achieved endpoint.
What are the market dynamics of the global atrial fibrillation therapeutics clinical trials sector?
The number of atrial fibrillation clinical trials conducted globally, has increased by 20% for the period 2016-2020. The average number of patients enrolled was highest in the year 2016. Out of the total clinical trials conducted, over 35% of trials have been sponsored by the company and more than 55% by institutions. As of November 2021, there were 302 clinical trials in progress and 1,118 trials were completed. The trials that were terminated/suspended or withdrawn accounted for 202. This was due to the lack of efficacy, safety, and lack of accrual of subjects. Out of 1,118 completed trials, 785 trials have results and 632 (81%) of trials reached endpoints.
What are the top regions and countries in the global atrial fibrillation therapeutics clinical trials sector?
In total there were 1,742 clinical trials conducted on atrial fibrillation, as of November 2021, of these 668 clinical trials were in Asia-Pacific. More than 35% of the clinical trials were conducted in Asia-Pacific. During the same period, Spain has the highest average patient enrollment of atrial fibrillation clinical trials.
Asia-Pacific: In the Asia-Pacific region, Japan has the highest number of atrial fibrillation clinical trials, as of November 2021, followed by China, South Korea, Australia, and India.
Europe: Among the European countries, Germany has the highest number of atrial fibrillation clinical trials, as of November 2021, followed by France, Italy, the UK, and Spain.
North America: In the country-wise analysis, the US has the highest number of atrial fibrillation clinical trials, as of November 2021, followed by Canada, and Mexico.
Middle East & Africa: Iran has the highest number of atrial fibrillation clinical trials, followed by Israel, South Africa, Egypt, and Jordan.
Central and South America: Brazil has the highest number of atrial fibrillation clinical trials in the region followed by Argentina, Chile, Colombia, and Peru.
G7 countries: Among the G7 (the US, the UK, Germany, France, Italy, Canada, and Japan) countries, Japan has the highest proportion of Atrial Fibrillation to Cardiovascular clinical trials as of November 2021. In total there were 1,147 clinical trials conducted on Atrial Fibrillation, as of November 2021 in G7 Countries, of these 294 clinical trials were in the US. During the same period of November 2021, there were 130 clinical trials in progress and 561 trials are completed. The trials that are terminated/suspended or withdrawn accounted for 112. This was due to the lack of efficacy, safety, and lack of accrual of subjects.
E7 countries: Among the E7 (Brazil, Russia, India, China, Mexico, Turkey, and Indonesia) countries, Russia has the highest proportion of Atrial Fibrillation to Cardiovascular clinical trials as of November 2021. During the same period, in total there were 445 clinical trials conducted on Atrial Fibrillation of these 212 clinical trials were in China. As of November 2021, there were 70 clinical trials in progress and 203 trials were completed. The trials that were terminated/suspended or withdrawn accounted to 35. This was due to the lack of efficacy, safety, and lack of accrual of subjects. As of November 2021, the majority of the trials were successfully completed.
Global atrial fibrillation therapeutics clinical trials sector, by regions
For more regional insights, download a free report sample
Which are the key companies in the global atrial fibrillation therapeutics clinical trials sector?
As of November 2021, Bayer AG has conducted the highest number of atrial fibrillation clinical trials, followed by Sanofi, and Daiichi Sankyo Co Ltd. The other major companies in the sector are Bristol-Myers Squibb Co, C. H. Boehringer Sohn AG & Co KG, Johnson & Johnson, AstraZeneca Plc, Pfizer Inc, Astellas Pharma Inc, and Medtronic Plc.
Global atrial fibrillation therapeutics clinical trials sector, by key companies
To know more about key companies, download a free report sample
Market report scope
Key countries | The US, Japan, China, Germany, Canada, South Korea, France, Italy, the UK, and Spain |
Key companies | Bayer AG, Sanofi, Daiichi Sankyo Co Ltd., Bristol-Myers Squibb Co, C. H. Boehringer Sohn AG & Co KG, Johnson & Johnson, AstraZeneca Plc, Pfizer Inc, Astellas Pharma Inc, and Medtronic Plc. |
Scope
- The report provides a snapshot of the global clinical trials landscape.
- Report provides top-level data related to the clinical trials by region, country (G7 & E7), trial status, trial phase, sponsor type, and endpoint status.
- The report reviews the top companies involved and enlists all trials (trial title, phase, and status) pertaining to the company.
- The report provides all the unaccomplished trials (terminated, suspended, and withdrawn) with the reason for unaccomplishment.
- The report provides enrollment trends for the past five years.
- Report provides the latest news for the past three months.
Reasons to Buy
- Assists in formulating key business strategies with regard to investment.
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost.
- Provides top-level analysis of the global clinical trials market which helps in identifying key business opportunities.
- Supports understanding of trials count and enrolment trends by country in the global therapeutics market.
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended, or withdrawn) trials.
- Facilitates clinical trial assessment of the indication on a global, regional, and country-level.
Sanofi
Daiichi Sankyo Co Ltd
Bristol-Myers Squibb Co
C. H. Boehringer Sohn AG & Co KG
Johnson & Johnson
AstraZeneca Plc
Pfizer Inc
Astellas Pharma Inc
Medtronic Plc
Table of Contents
Table
Figures
Frequently asked questions
-
What are the key countries in the global atrial fibrillation therapeutics clinical trials sector?
The key countries in the global atrial fibrillation therapeutics clinical trials sector are the US, Japan, China, Germany, Canada, South Korea, France, Italy, the UK, and Spain.
-
Which are the key companies in the global atrial fibrillation therapeutics clinical trials sector?
The key companies in the global atrial fibrillation therapeutics clinical trials sector are Bayer AG, Sanofi, Daiichi Sankyo Co Ltd., Bristol-Myers Squibb Co, C. H. Boehringer Sohn AG & Co KG, Johnson & Johnson, AstraZeneca Plc, Pfizer Inc, Astellas Pharma Inc, and Medtronic Plc.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.